All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in mantle cell lymphoma (MCL)?
Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?
To answer this question, Phillips describes a phase I trial investigating complete response rate and minimal residual disease (MRD) detectability when using this triplet regimen in untreated patients with MCL.
AACR 2017 | Poster 5179/22 – TK-216, the first in class FLI1 inhibitor, demonstrates in vivo and in vitro anti-tumor activity in Lymphoma
At AACR, one of the posters on display (5179 / 22) was titled “The first in class FLI1 inhibitor TK-216 presents...
Review | Therapies available or in clinical development for patients with aggressive mantle cell lymphoma in 2020
Chemoimmunotherapy with rituximab followed by autologous stem cell transplant (auto-HSCT) has been the gold standard and the only...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox